Baseline Platelet Count Predicts Infarct Size and Mortality after Acute Myocardial Infarction

Abstract

Introduction Platelets greatly contribute to cardiovascular diseases. We sought to explore the association of platelet counts with infarct size and outcome in patients presenting with acute ST-segment elevation MI (STEMI) treated with primary percutaneous coronary intervention (PPCI).

Methods and Results In this retrospective study, we grouped 1,198 STEMI patients into tertiles (T) based on platelet count on admission: T1 = 102–206 [10⁹ platelets/L] (n = 402), T2 = 207–259 [10⁹ platelets/L] (n = 396), and T3 = 260–921 [10⁹ platelets/L] (n = 400). Primary endpoint was 1-year all-cause mortality. Patients with highest platelet counts on admission showed the greatest area at risk and infarct size: area at risk (median) was 22.0% (interquartile range [IQR]: 12.0–39.8%) in T1, 21.0% (IQR: 11.0–37.1%) in T2, and 26.0% (IQR: 14.9–45.0%) of the left ventricle in T3 (p = 0.003); final infarct sizes after 7 to 14 days were as follows: 10.0% (IQR: 2.0–21.0%) in T1, 9.0% (IQR: 2.0–20.7%) in T2, and 12.0% (IQR: 3.0–27.3%) of the left ventricle in T3 (p = 0.015) as serial imaging revealed. At 1 year, 16 all-cause deaths occurred in T1, 5 in T2, and 22 in T3 (log-rank test, p = 0.006). After adjustment, T1 and T3 were associated with all-cause 1-year mortality (T1: hazard ratio [HR] = 3.40, 95% confidence interval [CI] = 1.23–9.54, p = 0.02; T3: HR = 3.55, 95% CI = 1.23–9.78, p = 0.01) compared with T2. At 5 years, all-cause mortality remained numerically higher in the T1 and T3.

Conclusions In patients with STEMI undergoing PPCI, low and high blood platelet levels on admission were associated with increased long-term mortality ([Fig. 1]).

Keywords

platelets - myocardial infarction - SPECT imaging - infarct size - outcome

• References

• 1 van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol 2019; 16 (03) 166-179
• 2 Walsh TG, Poole AW. Do platelets promote cardiac recovery after myocardial infarction: roles beyond occlusive ischemic damage. Am J Physiol Heart Circ Physiol 2018; 314 (05) H1043-H1048
• 3 Moggio A, Schunkert H, Kessler T, Sager HB. Quo Vadis? Immunodynamics of myeloid cells after myocardial infarction. Int J Mol Sci 2022; 23 (24) 15814
• 4 Sager HB, Kessler T, Schunkert H. Monocytes and macrophages in cardiac injury and repair. J Thorac Dis 2017; 9 (1, Suppl 1): S30-S35
• 5 Byrne RA, Rossello X, Coughlan JJ. et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care 2024; 13 (01) 55-161
• 6 Mauersberger C, Sager HB, Wobst J. et al. Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation. Nat Cardiovasc Res 2022; 1 (12) 1174-1186
• 7 Song PS, Ahn KT, Jeong JO. et al; KAMIR-NIH Investigators. Association of baseline platelet count with all-cause mortality after acute myocardial infarction. Eur Heart J Acute Cardiovasc Care 2020; 10 (02) 176-183
• 8 Małyszczak A, Łukawska A, Dyląg I, Lis W, Mysiak A, Kuliczkowski W. Blood platelet count at hospital admission impacts long-term mortality in patients with acute coronary syndrome. Cardiology 2020; 145 (03) 148-154
• 9 Nikolsky E, Grines CL, Cox DA. et al. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). Am J Cardiol 2007; 99 (08) 1055-1061
• 10 Iijima R, Ndrepepa G, Mehilli J. et al. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thromb Haemost 2007; 98 (04) 852-857
• 11 Mueller C, Neumann FJ, Hochholzer W. et al. The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction. Am Heart J 2006; 151 (06) 1214.e1-1214.e7
• 12 Dutsch A, Graesser C, Voll F. et al. Association of in-hospital hemoglobin drop with decreased myocardial salvage and increased long-term mortality in patients with acute ST-segment-elevation myocardial infarction. J Am Heart Assoc 2022; 11 (17) e024857
• 13 Sager HB, Husser O, Steffens S. et al. Time-of-day at symptom onset was not associated with infarct size and long-term prognosis in patients with ST-segment elevation myocardial infarction. J Transl Med 2019; 17 (01) 180
• 14 Ndrepepa G, Tiroch K, Fusaro M. et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2010; 55 (21) 2383-2389
• 15 Sharif D, Abu-Salem M, Sharif-Rasslan A, Rosenschein U. Platelet counts on admission affect coronary flow, myocardial perfusion and left ventricular systolic function after primary percutaneous coronary intervention. Eur Heart J Acute Cardiovasc Care 2017; 6 (07) 632-639
• 16 Ly HQ, Kirtane AJ, Murphy SA. et al; TIMI Study Group. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol 2006; 98 (01) 1-5
• 17 Tucker EI, Marzec UM, Berny MA. et al. Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates. Sci Transl Med 2010; 2 (37) 37ra45